All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000646-20 | A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal He... | 2005-12-27 | due-trials |
| Reported results | 2004-002795-42 | SHEPHERD: Safety in hemolytic PNH patients treated with Eculizumab: a multi-center open label research design study | 2006-10-18 | due-trials |
| Reported results | 2005-000043-28 | A Phase III Open label extension study of Eculizumab in patients with transfusion dependent hemolytic paroxysmal nocturnal hemoglobinuria PNH who have participated in Triumph C04-001 , Shepherd C0... | 2008-09-12 | due-trials |
| Not reported Terminated | 2006-002696-40 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects with... | 2007-02-08 | due-trials |
| Reported results | 2006-005968-13 | A 14-DAY, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE VIRAL KINETIC STUDY OF ELVUCITABINE VERSUS LAMIVUDINE ADMINISTERED ONCE DAILY TO HIV-1 INFECTED SUBJECTS WITH A DOCUMENTED M184V VARIANT | 2008-11-28 | due-trials |
| Reported results | 2006-006194-25 | An open-label, 48-week extension study of elvucitabine administered in combination with background antiretroviral agents in subjects who have completed 14 days of treatment in Protocol ACH443-014A | 2008-11-28 | due-trials |
| Reported results | 2008-006952-23 | AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS) | 2013-03-05 | due-trials |
| Reported results | 2008-006953-41 | AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS) | 2011-10-17 | due-trials |
| Reported results | 2008-006954-17 | AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) | 2013-10-10 | due-trials |
| Reported results | 2008-006955-28 | AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) | 2013-02-13 | due-trials |
| Reported results | 2009-009369-32 | Extension Study of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children with Hypophosphatasia (HPP) | 2017-02-07 | due-trials |
| Trial is outside EEC, and reported results | 2009-010402-11 | AN OPEN-LABEL MULTI-CENTER STUDY OF ECULIZUMAB IN CHILDREN AND ADOLESCENTS WITH A DIAGNOSIS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | bad-data | |
| Reported results Terminated | 2009-014669-13 | A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients with Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Tr... | 2011-03-16 | due-trials |
| Reported results | 2010-019630-28 | A RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING... | 2015-11-13 | due-trials |
| Reported results | 2010-019631-35 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN SENSITIZED RECIPIENTS OF A KIDNEY TRANSPLANT FROM ... | 2017-05-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-019850-42 | An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase alfa (human recombinant tissue nonspecific alkaline phosphatase fusion protein) in Infants and ... | 2017-04-26 | bad-data |
| Reported results | 2010-020310-28 | AN OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL OF ECULIZUMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME (aHUS) | 2014-01-08 | due-trials |
| Reported results | 2010-020326-18 | AN OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME | 2013-10-31 | due-trials |
| Reported results | 2010-022092-65 | A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in combina... | 2013-04-30 | due-trials |
| Reported results | 2011-000032-28 | AN OPEN LABEL, MULTICENTER, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SBC-102 IN CHILDREN WITH GROWTH FAILURE DUE TO LYSOSOMAL ACI... | 2018-01-03 | due-trials |
| Completed, but no date, and reported results | 2011-002691-17 | An open label, multi-center trial of eculizumab in patients with Shiga-toxin producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) | bad-data | |
| Reported results | 2011-002750-31 | A multicenter, randomized, placebo-controlled study of SBC-102 in patients with lysosomal acid lipase deficiency | 2018-12-11 | due-trials |
| Reported results | 2011-004287-30 | A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency | 2017-12-28 | due-trials |
| Reported results | 2013-001150-10 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO) | 2018-07-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-001151-12 | A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO) | 2021-07-12 | bad-data |
| Reported results | 2013-002191-41 | A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-MG-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (gMG) | 2019-01-15 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-002702-30 | A PHASE 2/3, MULTICENTER, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALX1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A Estudio abierto, ... | 2022-09-13 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2013-003400-39 | A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | 2017-10-16 | bad-data |
| Reported results | 2013-003588-73 | AN OPEN-LABEL PROOF OF CONCEPT PHASE IIA TRIAL OF ALXN1007 FOR THE TREATMENT OF NON-CRITERIA MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME | 2016-06-20 | due-trials |
| Reported results | 2013-003589-15 | A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG) | 2016-02-19 | due-trials |
| Reported results | 2013-004650-25 | A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multi-Center Study of Eculizumab for the Prevention of Delayed Graft Function after Kidney Transplantation in Adult Subjects at Increase... | 2016-11-22 | due-trials |
| Reported results | 2014-000533-22 | A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency | 2018-10-30 | due-trials |
| Reported results | 2014-001703-41 | A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older with an Extension Phase ... | 2018-11-07 | due-trials |
| Completed, but no date, and reported results | 2015-000753-20 | A PHASE I/II OPEN LABEL STUDY IN MPS IIIB SUBJECTS TO INVESTIGATE THE SAFETY, BIODISTRIBUTION, PHARMACOKINETICS, AND PHARMACODYNAMICS/EFFICACY OF SBC-103 ADMINISTERED INTRAVENOUSLY | bad-data | |
| Reported results | 2015-000809-39 | An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (human recombinant tissue-nonspecific alkaline phosphatase fusion protein) Treatment for Patients with Infantile- or Juvenile-onse... | 2018-03-08 | due-trials |
| Trial is outside EEC, and reported results | 2015-001128-52 | A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Historical Control Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ENB-0040 (Human Recombinant Tissue-Nonsp... | bad-data | |
| Reported results Terminated | 2015-001983-20 | A Phase I/II Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intrav... | 2017-08-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-002674-20 | A Phase 2, Open-Label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Pa... | 2022-01-12 | bad-data |
| Reported results | 2015-003131-35 | A Phase 2a Randomized, Multi-center, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients with Pediatric-Onset Hypophosphatasia Eine offene, randomisierte, multiz... | 2017-06-21 | due-trials |
| Reported results | 2015-003135-35 | EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH aHUS, INCLUDING GENETICS, BIOMARKERS, AND TREATMENT | 2017-09-21 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-001384-37 | An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients with Refractory Generalized Myasthenia Gravis (gMG) | 2023-11-06 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-002025-11 | A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Na¿ve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) STUDIO DI FASE 3... | 2023-02-28 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-002026-36 | A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | 2022-04-08 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-002027-29 | Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Na¿ve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Studio a braccio singolo su ALXN1210 somministrato ... | 2023-01-24 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-002499-29 | A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS) | 2022-12-20 | bad-data |
| Reported results | 2016-002652-25 | A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | 2019-02-27 | due-trials |
| Reported results | 2016-003525-42 | A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients with Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproli... | 2019-01-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003526-16 | A Phase 2 Open-label Study of ACH-0144471 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy | 2023-01-05 | bad-data |
| Other | 2017-000663-33 | A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G) | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-000665-79 | An Open-Label Study to Evaluate Efficacy and Safety of Long-term Treatment with ACH-0144471 in Patients with PNH who Completed Clinical Study ACH471-100 | 2022-01-03 | bad-data |
| Trial is outside EEC, and reported results | 2017-001831-38 | A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Ph... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-002370-39 | A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal ... | 2023-08-31 | bad-data |
| Reported results | 2017-002674-39 | An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471 | 2021-03-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-002820-26 | A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) | 2022-08-25 | bad-data |
| Trial is outside EEC, and reported results | 2017-003153-42 | Extension Study of Protocol ENB-006-09 Evaluating the Long-Term Safety and Efficacy of Asfotase Alfa (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Children with Hypopho... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004135-36 | A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older wi... | 2023-06-30 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002620-17 | A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR | 2023-08-09 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-003243-39 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia G... | 2023-05-25 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-001829-26 | A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder | 2023-07-31 | bad-data |
| Ongoing | 2019-003352-37 | A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) | not-yet-due | |
| Other | 2019-003440-74 | Phase 4, Single-Arm Study of Ravulizumab in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with High-Dose Eculizumab | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-003711-60 | A Phase 2, single-arm, pathologist-blinded study using liver biopsy specimens to assess copper concentration and histopathologic changes in patients with Wilson disease who are treated with ALXN1840 f... | 2023-05-17 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-003829-18 | A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular H... | 2024-01-16 | bad-data |
| Ongoing | 2019-003830-17 | A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients a... | not-yet-due | |
| Reported results Terminated | 2019-004055-37 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, d... | 2020-05-28 | due-trials |
| Ongoing | 2019-004254-28 | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscras... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-004619-30 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic ... | 2021-10-17 | bad-data |
| Other | 2020-000144-61 | A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT) | not-yet-due | |
| Reported results | 2020-000374-21 | PROSPECTIVE, OPEN-LABEL STUDY OF ANDEXANET ALFA IN PATIENTS RECEIVING A FACTOR XA INHIBITOR WHO REQUIRE URGENT SURGERY (ANNEXA-S) | 2022-01-25 | due-trials |
| Ongoing | 2020-000713-32 | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscras... | not-yet-due | |
| Other | 2020-000761-16 | A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (T... | not-yet-due | |
| Other | 2020-001104-41 | A Phase 2, open-label study to assess copper and molybdenum balance in participants with Wilson disease treated with ALXN1840 | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-001497-30 | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pne... | 2021-09-01 | bad-data |
| Other | 2020-001537-13 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephr... | not-yet-due | |
| Reported results | 2020-005328-13 | A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated with ... | 2022-12-22 | due-trials |
| Reported results | 2020-005832-31 | Efficacy of ALXN1840 on human hepatic copper uptake quantified with 64CuCl2 PET/CT-scan. Effekten af ALXN1840 på kobberoptag i leveren målt ved 64CuCl2 PET/CT | 2022-07-04 | due-trials |
| Reported results | 2021-001015-82 | A multicenter, randomized, controlled, open-label, rater-blinded study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ALXN1840 versus standard of care in pediatric participant... | 2023-06-27 | due-trials |
| Other | 2021-001198-22 | A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-001200-15 | A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis. | 2024-05-08 | bad-data |
| Completed, but no date, and reported results Terminated | 2021-001211-90 | A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo- Controlled Study of ALXN1830 Administered Subcutaneously in Patients with Warm Autoimmune Hemolytic Anemia (WAIHA) Studio di f... | bad-data | |
| Completed, report not yet due | 2021-001229-26 | A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis | 2024-04-03 | not-yet-due |
| Other | 2021-001426-22 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobu... | not-yet-due | |
| Other | 2021-004253-22 | A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients with Paroxysmal Nocturnal Hemoglobin... | not-yet-due | |
| Other | 2021-006075-42 | A Phase 2/3 Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aq... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2022-000460-21 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. | 2023-10-16 | bad-data |